Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 165, Issue 4, Pages 510-518
Publisher
Wiley
Online
2014-03-03
DOI
10.1111/bjh.12780
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma
- (2013) M. Dreyling et al. ANNALS OF ONCOLOGY
- Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study
- (2013) Andre Goy et al. JOURNAL OF CLINICAL ONCOLOGY
- PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors
- (2012) F. Meric-Bernstam et al. CLINICAL CANCER RESEARCH
- Counteracting Autophagy Overcomes Resistance to Everolimus in Mantle Cell Lymphoma
- (2012) L. Rosich et al. CLINICAL CANCER RESEARCH
- NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy
- (2012) Monica Civallero et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma
- (2012) C. Renner et al. HAEMATOLOGICA
- The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells
- (2012) Areumnuri Kim et al. LEUKEMIA RESEARCH
- Genome Sequencing Identifies a Basis for Everolimus Sensitivity
- (2012) G. Iyer et al. SCIENCE
- Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma
- (2012) Sara Galimberti Cancer Management and Research
- Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study
- (2011) Stephen M Ansell et al. LANCET ONCOLOGY
- PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs
- (2011) B Weigelt et al. ONCOGENE
- Is There a Role for “Watch and Wait” in Patients With Mantle Cell Lymphoma?
- (2011) Peter Martin et al. SEMINARS IN HEMATOLOGY
- Targeting the PI3K/AKT/mTOR Pathway in Non-Hodgkin’s Lymphoma: Results, Biology, and Development Strategies
- (2011) Jonathan H. Schatz Current Oncology Reports
- Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era
- (2010) P. Perez-Galan et al. BLOOD
- Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
- (2010) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL INVESTIGATION
- A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
- (2010) T E Witzig et al. LEUKEMIA
- Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial
- (2009) Owen A. O’Connor et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- (2009) Georg Hess et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
- (2008) A. Goy et al. ANNALS OF ONCOLOGY
- Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma
- (2008) J. Dal Col et al. BLOOD
- Delineation of distinct tumour profiles in mantle cell lymphoma by detailed cytogenetic, interphase genetic and morphological analysis
- (2008) Tiemo Katzenberger et al. BRITISH JOURNAL OF HAEMATOLOGY
- Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma
- (2008) Stephen M. Ansell et al. CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started